ethambutol has been researched along with 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bera, S; Mondal, D | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Barbara-Burnham, L; Bermudez, LE; Inderlied, CB; Wu, M; Young, LS | 1 |
| Bermudez, LE; Inderlied, CB; Kolonoski, P; Young, LS | 1 |
| Amitani, R; Kuze, F; Murayama, T; Suzuki, K; Tanaka, E; Yamamoto, T | 2 |
| Piddock, LJ; Ricci, V | 1 |
| Chase, SE; Cynamon, MH; Lenaerts, AM | 1 |
1 review(s) available for ethambutol and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
7 other study(ies) available for ethambutol and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
Topics: Antibiotics, Antitubercular; Cell Line; Clarithromycin; Ethambutol; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Rifamycins | 1994 |
Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.
Topics: Animals; Antibiotics, Antitubercular; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Female; Mice; Mice, Inbred C57BL; Mycobacterium avium; Rifamycins; Tuberculosis | 1994 |
In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Isoniazid; Male; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Rifamycins; Tuberculosis | 1996 |
Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Clarithromycin; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Kanamycin; Lung; Male; Mice; Mycobacterium avium Complex; Rifampin; Rifamycins; Spleen; Tuberculosis | 1996 |
Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis.
Topics: Antibiotics, Antitubercular; Carbon Radioisotopes; Colony Count, Microbial; Ethambutol; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Polysorbates; Reserpine; Rifamycins | 2000 |
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Pyrazinamide; Rifampin; Rifamycins; Tuberculosis | 2000 |